AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16268392
Drug: Ranir Whitening
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranir Whitening Wraps (WW2) used twice a day
Trial: 16268392
Drug: Crest Whitestrips
RxNorm normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crest Whitestrips Premium (WP2) used twice a day
Trial: 12162472
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg morphine alone
Trial: 12162472
Drug: 15-minute TEAS
RxNorm normalized name: tea tree oil 0.15 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-minute TEAS plus morphine
Trial: 9861593
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of magnesium (as MgO)
Trial: 7635854
Drug: Clomipramine or
RxNorm normalized name: clomipramine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine or Fluoxetine
Trial: 31685913
Drug: Modified aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified aerobic training with a load on the lower limbs (MG)
Trial: 26856247
Drug: Prednisone (PD)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PD) treatment over 4.3 years
Trial: 26856247
Drug: High-dose anti-metabolite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose anti-metabolite treatment arm
Trial: 23386641
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 4800 IU daily
Trial: 23386641
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 800 IU daily
Trial: 23386641
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements to maintain total calcium intake of 1200-1400 mg/d
Trial: 19586229
Drug: Oral methadone-naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone-naloxone in a 50:1 ratio
Trial: 19586229
Drug: Intramuscular methadone-naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular methadone-naloxone in a 50:1 ratio
Trial: 8006397
Drug: 4-week course
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week course of prednisolone followed by 2 weeks of no treatment and then a 12-week course of human lymphoblastoid interferon, 4 to 6 MU/m2 intramuscularly
Trial: 2920071
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg of alcohol (12.5%, v/v)
Trial: 29241576
Drug: 1 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 300 mL plum juice
Trial: 29241576
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 100 mL plum juice
Trial: 25487567
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg · kg(‐1) (Group D1)
Trial: 25487567
Drug: Dexmedetomidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2 μg · kg(‐1) (Group D2)
Trial: 19532851
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) patch
Trial: 16214329
Drug: PUFA n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA n-3 supplementation (3.6 g daily for 3 months)
Trial: 11425671
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) therapy
Trial: 9260214
Drug: Schwarz strain
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz strain measles vaccine (SWMV)
Trial: 9260214
Drug: Edmoston-Zagreb strain
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmoston-Zagreb strain measles vaccine (EZMV)
Trial: 8033606
Drug: Retinoic acid
RxNorm normalized name: Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retinoic acid (RA) alone at an oral dose of 45-60 mg/m2/d
Trial: 8033606
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (RA and chemotherapy)
Trial: 8033606
Drug: RA as
RxNorm normalized name: Flora Assist Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA as continuation therapy (Group A)
Trial: 8033606
Drug: RA and
RxNorm normalized name: Cascara and senna only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA and chemotherapy alternately (Group C)
Trial: 3885963
Drug: Flupirtine 100
RxNorm normalized name: flupirtine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine 100 mg capsules
Trial: 3885963
Drug: Pentazocine 50
RxNorm normalized name: pentazocine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 50 mg capsules
Trial: 25156398
Drug: Attention training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention training towards positive stimuli (ATP) combined with one-session treatment (OST)
Trial: 25156398
Drug: Attention training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention training control (ATC) combined with one-session treatment (OST)
Trial: 20584565
Drug: 28 g
RxNorm normalized name: SM Syringe 28 g, 0.5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 g acetogenic fibers (acacia gum and pectin)
Trial: 20584565
Drug: Fiber treatment
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber treatment
Trial: 15931646
Drug: 20.8 mg
RxNorm normalized name: sulfur 20.8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.8 mg of sodium iron gluconate at the end of each dialysis session (Group A)
Trial: 15931646
Drug: 62.5 mg
RxNorm normalized name: quinine 162.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5 mg of sodium iron gluconate only at the end of the 1st dialysis session of the week (Group B)
Trial: 2580171
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg orally (acute and fasting)
Trial: 2580171
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg orally (with concomitant food intake)
Trial: 2580171
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg orally (without concomitant food intake)
Trial: 2580171
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg three times a day for 4-5 weeks (chronic treatment)
Trial: 2580171
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg (twice daily)
Trial: 26400628
Drug: Topical antifungal
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungal treatment + oral antifungal
Trial: 26400628
Drug: Topical antifungal
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungal treatment + ICAMB + oral antifungal
Trial: 26400628
Drug: Topical antifungal
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungal treatment + drainage of hypopyon + ICAMB + oral antifungal
Trial: 21162931
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg oral midazolam (Group I)
Trial: 18519835
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) consisting of seven standardized techniques for 20 minutes.
Trial: 18519835
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (light touch applied to the same anatomic regions for 20 minutes).
Trial: 15741580
Drug: BIS-blinded group
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS-blinded group (single dose)
Trial: 15741580
Drug: BIS-unblinded group
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS-unblinded group (single dose)
Trial: 15741580
Drug: BIS-blinded group
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS-blinded group (multiple doses)
Trial: 15741580
Drug: BIS-unblinded group
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS-unblinded group (multiple doses)
Trial: 10566703
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.i.d. for 12 weeks
Trial: 9012256
Drug: lerivon (L)
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lerivon (L) for 1 month
Trial: 25434303
Drug: Matched unrelated
RxNorm normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched unrelated hematopoietic cell transplantation (HCT) in first remission for patients with FLT3-ITD allelic ratio >0.8, poor day +15 marrow blast clearance, and adverse karyotypes; allogeneic HCT in high-risk AML performed in aplasia after induction chemotherapy
Trial: 23504636
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD with PegIFN/RBV (48 weeks)
Trial: 23504636
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD without lead-in (48 weeks)
Trial: 23504636
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg BID with lead-in (48 weeks)
Trial: 23504636
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD/LI (rerandomized to 48 weeks treatment)
Trial: 23504636
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD/LI, 240 mg QD, and 240 mg BID/LI (adverse events)
Trial: 23504636
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg BID
Trial: 19136900
Drug: Fluvastatin (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (40-80 mg daily)
Trial: 12948282
Drug: α-tocopherol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-tocopherol supplementation (50 mg/day for five to eight years)
Trial: 7780491
Drug: dexfenfluramine (dF)
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexfenfluramine (dF) 30 mg/d
Trial: 2180388
Drug: Daily mud
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mud packs
Trial: 2180388
Drug: Daily hot
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily hot sulphur baths
Trial: 2180388
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mud packs and hot sulphur baths
Trial: 7462801
Drug: cholestyramine (8g)
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cholestyramine (8g) administered 30 min prior to test
Trial: 17570410
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily from postoperative days 1 to 90
Trial: 17570410
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg per day as needed
Trial: 11199942
Drug: Olanzapine (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (daily doses ranging from 2.5 to 17.5 mg/day for up to 6 weeks)
Trial: 11199942
Drug: Haloperidol (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (exact dosage and duration not specified)
Trial: 11199942
Drug: Placebo (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (exact dosage and duration not specified)
Trial: 8006647
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (Epilim EC enteric coated 200 mg tablets twice daily)
Trial: 8006647
Drug: Carbamazepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (100 mg twice daily increasing to 200 mg twice daily in week 2)
Trial: 19160404
Drug: Topical amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical amphotericin B
Trial: 14970005
Drug: BCAA mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA mixture intake (0, 20, 30, 50, 60, 70, 90, 110, and 130 mg.kg(‐1).day(‐1))
Trial: 9854277
Drug: Supervised fitness
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised fitness training under bright light (2500-4000 lx) 2-3 times weekly for 8 weeks
Trial: 9854277
Drug: Supervised fitness
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised fitness training under ordinary light (400-600 lx) 2-3 times weekly for 8 weeks
Trial: 8582955
Drug: Cabergoline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 1.0 mg oral administration for inhibition of puerperal lactation
Trial: 8582955
Drug: Cabergoline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 1.0 mg (0.25 mg twice daily for 2 days) for suppression of established lactation
Trial: 8582955
Drug: Cabergoline 1-2
RxNorm normalized name: cabergoline 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 1-2 mg weekly doses (twice weekly schedule) for hyperprolactinaemic amenorrhoea
Trial: 2121406
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 g with five-minute tourniquet inflation
Trial: 2121406
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 g with two-minute tourniquet inflation
Trial: 2121406
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 g with one-minute tourniquet inflation
Trial: 28668719
Drug: Rapid acting
RxNorm normalized name: insulin inhalation, rapid acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid acting insulin analog (RAIA)
Trial: 28668719
Drug: Nurse perceptions
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse perceptions of RAIA dosing
Trial: 28668719
Drug: Nurse perceptions
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse perceptions of electronic dosing calculator and patient reminder
Trial: 19167693
Drug: Desvenlafaxine 100
RxNorm normalized name: desvenlafaxine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 100 mg
Trial: 19167693
Drug: Desvenlafaxine 150
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 150 mg
Trial: 9638033
Drug: Caffeine (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4.5 mg caffeine/kg fat-free mass)
Trial: 8206809
Drug: Sulpiride 150
RxNorm normalized name: (±)-sulpiride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 150 mg
Trial: 8206809
Drug: Sulpiride 300
RxNorm normalized name: (±)-sulpiride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 300 mg
Trial: 4885615
Drug: Dipyridamole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (400 mg daily for 14 months, then 800 mg daily for 11 months)
Trial: 30365461
Drug: Laser-assisted corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-assisted corticosteroid delivery (topical triamcinolone acetonide 20 mg/mL)
Trial: 30365461
Drug: Laser-assisted 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-assisted 5-fluorouracil delivery (topical 5-fluorouracil 50 mg/mL)
Trial: 23244536
Drug: 1.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/d c9, t11 CLA for 16 weeks
Trial: 23244536
Drug: 3.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g/d c9, t11 CLA for 16 weeks
Trial: 19032576
Drug: ondansetron 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 0.5 mg/d
Trial: 19032576
Drug: sertraline 200
RxNorm normalized name: sertraline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline 200 mg/d
Trial: 17522585
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) 70 microg/kg administered intravenously
Trial: 2649461
Drug: Topical infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical infusion of metronidazole solution
Trial: 2649461
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without metronidazole
Trial: 31952545
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of zoledronic acid to consolidation chemotherapy
Trial: 20439056
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (average 10 sessions)
Trial: 15824361
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 1,300 mg/day
Trial: 12066083
Drug: Subcutaneous stitch
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous stitch closure
Trial: 12066083
Drug: Subcutaneous drain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous drain placement
Trial: 10910540
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (RI) infusion (n = 20); ratio of infusion glucose to regular insulin was 10‐15 gm glucose to 1 unit RI, glucose infusion rate maintained at least 6 mg/Kg/min.
Trial: 10910540
Drug: Kayexalate resin
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kayexalate resin enema (n = 20); dose of Kayexalate was 1 gm/Kg body weight given rectally every four hours.
Trial: 8584194
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural analgesia with bupivacaine and morphine
Trial: 8584194
Drug: Endovenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous analgesia with morphine boluses
Trial: 6295422
Drug: sequential hemi-body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential hemi-body irradiation (HBI)
Trial: 6295422
Drug: 3-drug cyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-drug cyclic chemotherapy (CC)
Trial: 31272528
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg memantine tablet formulation A
Trial: 31272528
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg memantine tablet formulation B
Trial: 15189492
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (mean dose 0.33 +/- 0.15; range 0.09-0.66 units/kg/d) administered twice daily
Trial: 8083823
Drug: Concomitant medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant medications (average of 7.1 drugs per month for AIDS patients)
Trial: 8083823
Drug: Concomitant medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant medications (average of 3.1 drugs per month for ARC patients)
Trial: 8083823
Drug: Concomitant medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant medications (average of 2.7 drugs per month for asymptomatic patients)
Trial: 8083823
Drug: Drug classes
RxNorm normalized name: VARIOUS DRUG CLASSES IN ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug classes used
Trial: 8083823
Drug: Prescription vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription vs. over-the-counter drugs
Trial: 8083823
Drug: Antivirals and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antivirals and vitamins consumption
Trial: 8083823
Drug: Analgesics or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics or antipyretics consumption